6283966
Last Update Posted: 2025-04-24
Recruiting
All Genders accepted | 40 Years-80 Years |
5000 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.
Eligibility
Relevant conditions:
COPD (Chronic Obstructive Pulmonary Disease)
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Data sourced from ClinicalTrials.gov